Latest Insider Transactions at Edwards Lifesciences Corp (EW)
This section provides a real-time view of insider transactions for Edwards Lifesciences Corp (EW). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Edwards Lifesciences Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Edwards Lifesciences Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 21
2024
|
Daveen Chopra CVP, TMTT |
SELL
Open market or private sale
|
Direct |
8,200
-13.7%
|
$705,200
$86.71 P/Share
|
|
Feb 21
2024
|
Daveen Chopra CVP, TMTT |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+18.45%
|
$413,000
$59.26 P/Share
|
|
Feb 18
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
188
-1.08%
|
$16,168
$86.1 P/Share
|
|
Feb 17
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
150
-0.85%
|
$12,900
$86.1 P/Share
|
|
Feb 16
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
207
-1.17%
|
$17,802
$86.04 P/Share
|
|
Feb 16
2024
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
317
-0.15%
|
$27,262
$86.04 P/Share
|
|
Feb 16
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
174
-0.9%
|
$14,964
$86.04 P/Share
|
|
Feb 15
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
27,000
-43.68%
|
$2,295,000
$85.62 P/Share
|
|
Feb 15
2024
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+30.4%
|
$972,000
$36.75 P/Share
|
|
Feb 13
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
20,000
-36.49%
|
$1,720,000
$86.46 P/Share
|
|
Feb 13
2024
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+26.73%
|
$720,000
$36.75 P/Share
|
|
Feb 13
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
11,000
-10.99%
|
$946,000
$86.08 P/Share
|
|
Feb 13
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+17.89%
|
$396,000
$36.75 P/Share
|
|
Feb 12
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Open market or private sale
|
Direct |
12,210
-48.27%
|
$1,062,270
$87.0 P/Share
|
|
Feb 12
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
12,210
+32.55%
|
$439,560
$36.75 P/Share
|
|
Feb 08
2024
|
Heisz Leslie Stone Director |
SELL
Open market or private sale
|
Direct |
7,056
-20.73%
|
$606,816
$86.45 P/Share
|
|
Feb 08
2024
|
Heisz Leslie Stone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,056
+17.17%
|
$254,016
$36.86 P/Share
|
|
Feb 05
2024
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-33.13%
|
$2,582,800
$88.06 P/Share
|
|
Feb 05
2024
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+46.45%
|
$1,056,600
$36.75 P/Share
|
|
Feb 01
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,255
-27.37%
|
$565,890
$78.29 P/Share
|
|
Feb 01
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,255
+21.49%
|
$261,180
$36.75 P/Share
|
|
Jan 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
10,000
-20.2%
|
$750,000
$75.67 P/Share
|
|
Jan 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.81%
|
$360,000
$36.75 P/Share
|
|
Jan 05
2024
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-46.54%
|
$2,142,550
$73.2 P/Share
|
|
Jan 05
2024
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+46.45%
|
$1,056,600
$36.75 P/Share
|
|
Dec 29
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,510
-42.98%
|
$1,102,760
$76.55 P/Share
|
|
Dec 29
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,510
+30.06%
|
$522,360
$36.75 P/Share
|
|
Dec 15
2023
|
Daveen Chopra CVP, TMTT |
SELL
Open market or private sale
|
Direct |
7,000
-22.62%
|
$546,000
$78.25 P/Share
|
|
Dec 15
2023
|
Daveen Chopra CVP, TMTT |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+18.45%
|
$413,000
$59.26 P/Share
|
|
Dec 13
2023
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-31.89%
|
$2,171,900
$74.56 P/Share
|
|
Dec 13
2023
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+46.45%
|
$1,056,600
$36.75 P/Share
|
|
Dec 13
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
8,658
-3.89%
|
$614,718
$71.86 P/Share
|
|
Dec 13
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
8,658
+3.75%
|
$389,610
$45.28 P/Share
|
|
Dec 13
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
8,000
-16.84%
|
$568,000
$71.86 P/Share
|
|
Dec 13
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+14.41%
|
$288,000
$36.75 P/Share
|
|
Dec 06
2023
|
Daveen Chopra CVP, TMTT |
SELL
Open market or private sale
|
Direct |
3,500
-12.75%
|
$245,000
$70.0 P/Share
|
|
Dec 06
2023
|
Daveen Chopra CVP, TMTT |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+11.31%
|
$206,500
$59.26 P/Share
|
|
Nov 13
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
6,000
-6.81%
|
$390,000
$65.19 P/Share
|
|
Nov 13
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+11.65%
|
$216,000
$36.75 P/Share
|
|
Nov 13
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
8,660
-1.31%
|
$562,900
$65.51 P/Share
|
|
Nov 13
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
8,660
+3.75%
|
$389,700
$45.28 P/Share
|
|
Nov 06
2023
|
Michael A Mussallem Director |
BUY
Bona fide gift
|
Indirect |
371,689
+8.43%
|
-
|
|
Nov 06
2023
|
Michael A Mussallem Director |
SELL
Bona fide gift
|
Indirect |
371,689
-100.0%
|
-
|
|
Nov 03
2023
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-86.74%
|
$1,966,450
$67.18 P/Share
|
|
Nov 03
2023
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+46.45%
|
$1,056,600
$36.75 P/Share
|
|
Oct 31
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,255
-27.37%
|
$449,810
$62.66 P/Share
|
|
Oct 31
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,255
+21.49%
|
$261,180
$36.75 P/Share
|
|
Oct 13
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-5.78%
|
$345,000
$69.92 P/Share
|
|
Oct 13
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+10.1%
|
$180,000
$36.75 P/Share
|
|
Oct 13
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
8,660
-1.97%
|
$597,540
$69.94 P/Share
|